EBS Equity Snapshot

NWRN Weekly Equity Report

Newron Pharmaceuticals S.p.A.

Interactive chart JSON snapshot
Latest Close 12.06 CHF 12 Jun 2026
1W Return -1.1% latest completed week
4W Return -15.2% short-term follow-through
12W Return -17.4% quarterly tape
Trend Breadth 50.0% 26 of 52 weeks active
Volume Ratio 0.9x vs 13-week average
Company Brief

What the company does

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. It has a strategic partnership with …

Snapshot

What the weekly tape is saying

NWRN closed the latest completed week at 12.06 CHF. The 4-week return is -15.2% and the 12-week return is -17.4%. Trend Signal is inactive, Market Dynamics is -1.28. Setup signature: Risk-first tape with a 15/100 composite read.

Trend Signal Inactive
Market Dynamics No fresh buy
Price vs Trend -32.3%
Volume 0.9x
Setup Cockpit

A compressed read of the whole setup

The radar blends trend persistence, momentum, Market Dynamics, Relative Strength, volume confirmation, and risk control into one weekly cockpit.

Composite setup radar

Scoreboard

Trend 28 Persistence of active Trend Signal over the last year and current streak.
Momentum 0 Blend of 4-week and 12-week follow-through.
Dynamics 27 Latest Market Dynamics and whether pressure has improved over four weeks.
Relative Strength 0 Relative leadership and short-term RS change.
Volume 36 Participation compared with the 13-week volume baseline.
Risk Control 0 Drawdown and recent weekly volatility pressure.

16-week signal tape

27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun
Weekly return bar Trend Signal dot Positive Market Dynamics dot
Price Action

Price, Trend Line, and Fair Value

Weekly price context with the latest close, trend position, Fair Value gap, drawdown, and 52-week range location.

52-week price path

Price Trend Line Fair Value

Price map

Trend Line
17.82 CHF
Vs Trend Line
-32.3%
Fair Value
9.80 CHF
Vs Fair Value
23.0%
52W High
31.85 CHF
52W Low
6.50 CHF
Drawdown
-62.1%
Range Position
21.9%
Momentum

Returns and trend persistence

Return windows separate the latest week from short-term and medium-term follow-through.

Return windows

1W -1.1%
4W -15.2%
12W -17.4%
26W -40.1%
52W 66.3%

Trend read

Active Streak
0 weeks
52W Active Weeks
26
52W Active Breadth
50.0%
Sector Scope
CH Healthcare
Sector Rank
26 of 41
Sector Percentile
37.5%
Peer Context

Sector and industry pulse

Peer breadth helps separate a stock-specific move from a broader group rotation.

Market Dynamics

Pressure, Relative Strength, and expectation

Market Dynamics and Relative Strength show whether buying pressure and relative leadership are confirming the price move.

Dynamics path

Market Dynamics Relative Strength

Signal state

Market Dynamics
-1.28
4W MD Change
3.3%
Relative Strength
-21.56
4W RS Change
-1158.9%
Expectation
Undecided
Probability
45.34%
Volume

Participation and confirmation

Volume tells us whether the latest weekly move is being confirmed by unusual participation.

52-week volume profile

Volume map

Latest Volume
323.4K
13W Average
373.0K
52W Average
513.9K
Vs 13W
0.9x
Vs 52W
0.6x
Risk Anatomy

Volatility, downside weeks, and return shape

A compact risk profile shows whether the move is steady, volatile, or being driven by sharp one-week jumps.

26-week return distribution

Risk map

13W Volatility
5.7%
52W Volatility
9.2%
Upside Weeks
26
Downside Weeks
26
Downside Breadth
50.0%
Avg Gain / Loss
8.4% / -5.7%
Context

Classification, opportunities, risks, and watch points

Top-level read across company classification, constructive evidence, caution points, and the next things that matter.

Classification

Exchange
EBS
Country
CH
Sector
Healthcare
Industry
Biotechnology
Currency
CHF
Market Cap
283.4M

Opportunity signals

  • Price is above Fair Value, showing premium demand versus the model.

Risk signals

  • Trend Signal is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Market Dynamics is negative, which weakens the current setup.
  • The share remains more than 20% below its 52-week high.

Watch next

  • Trend Line remains the key weekly regime level.
  • Market Dynamics is the pressure gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Weekly Tape

Recent completed weeks

The latest weekly rows behind the report snapshot.

Week Close Return Trend Fair Value MD RS Volume Signal
12 Jun 2026 12.06 CHF -1.1% 17.82 CHF 9.80 CHF -1.28 -21.56 323.4K Off
5 Jun 2026 12.20 CHF -10.4% 17.92 CHF 9.75 CHF -1.30 -18.35 395.8K Off
29 May 2026 13.62 CHF -3.0% 17.99 CHF 9.70 CHF -1.37 -9.44 169.8K Off
22 May 2026 14.04 CHF -1.3% 18.02 CHF 9.64 CHF -1.37 -5.71 211.6K Off
15 May 2026 14.22 CHF 4.6% 18.02 CHF 9.58 CHF -1.32 -1.71 398.9K Off
8 May 2026 13.60 CHF -4.9% 18.00 CHF 9.52 CHF -1.30 -4.40 379.4K Off
1 May 2026 14.30 CHF -8.2% 18.05 CHF 9.46 CHF -1.25 0.88 414.0K Off
24 Apr 2026 15.58 CHF -5.2% 18.01 CHF 9.40 CHF -1.23 10.49 251.6K Off
17 Apr 2026 16.44 CHF 9.3% 17.84 CHF 9.33 CHF -1.15 15.57 447.0K Off
10 Apr 2026 15.04 CHF -1.1% 17.65 CHF 9.25 CHF -1.19 9.01 215.6K Off
3 Apr 2026 15.20 CHF 2.6% 17.44 CHF 9.18 CHF -1.17 13.13 342.1K Off
27 Mar 2026 14.82 CHF 1.5% 17.25 CHF 9.12 CHF -1.13 15.30 839.0K Off
20 Mar 2026 14.60 CHF -11.2% 17.04 CHF 9.06 CHF -1.13 17.11 460.6K Off
13 Mar 2026 16.44 CHF -6.8% 16.80 CHF 9.01 CHF -1.01 27.86 385.6K On